Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Posts Drop in Q1 Revenue, Widened Losses

NEW YORK, May 11 (GenomeWeb News) - Transgenomic today reported a drop in first-quarter earnings, accompanied by widening net losses and reduced R&D spending.

Transgenomic's revenues for the quarter ended March 31, 2004, were $8.6 million, down 9 percent from $9.5 million in the first quarter of 2004. CEO Collin D'Silva said that revenue from sales of bioconsumables during the quarter increased 35 percent year-over-year.

The net loss for the quarter was $3.9 million, or $.13 per share, and included a non-cash finance charge of $503,000. This compares to a net loss of $3.6 million, or $.15 per share, for the first quarter of 2003, which included a goodwill impairment charge of $4.8 million.

The company cited its Boulder, Colo.-based specialty oligonucleotide manufacturing facility, which generated $679,000 in revenues and incurred $1.5 million of manufacturing expenses during the quarter, as having a particularly negative impact on its bottom line.

Transgenomic's R&D spending was $1.9 million during the first quarter of 2004, down from $2.3 million in the prior-year period.

The company shored up its cash position by $1.3 million during the quarter, which it closed with $2.5 million of cash, cash equivalents, and short-term investments on hand. As of Dec. 31, 2003, Transgenomic had $1.2 million in cash, cash equivalents, and short-term investments.

Mitch Murphy, Transgenomic's Interim CFO, predicted revenues in the range of $9.0 to $9.5 million for the second quarter of 2004, adding, "we continue to monitor our expenses and will look for opportunities to continue to achieve incremental reductions."

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.